Your browser doesn't support javascript.
loading
Rational Combination of CRM1 Inhibitor Selinexor and Olaparib Shows Synergy in Ovarian Cancer Cell Lines and Mouse Models.
Handley, Katelyn F; Rodriguez-Aguayo, Cristian; Ma, Shaolin; Stur, Elaine; Joseph, Robiya; Bayraktar, Emine; Dasari, Santosh K; Nguyen, Nghi; Powell, Reid T; Sobieski, Mary; Ivan, Cristina; Kim, Mark; Umamaheswaran, Sujanitha; Glassman, Deanna; Wen, Yunfei; Amero, Paola; Stephan, Clifford; Coleman, Robert L; Landesman, Yosef; Westin, Shannon N; Ram, Prahlad T; Sood, Anil K.
Afiliación
  • Handley KF; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Rodriguez-Aguayo C; Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Morsani College of Medicine, University of South Florida, Tampa, Florida.
  • Ma S; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Stur E; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Joseph R; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Bayraktar E; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Dasari SK; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Nguyen N; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Powell RT; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Sobieski M; HTS Screening Core, Center for Translational Cancer Research, Institute of Biosciences and Technology, College of Medicine, Texas A&M University, Houston, Texas.
  • Ivan C; HTS Screening Core, Center for Translational Cancer Research, Institute of Biosciences and Technology, College of Medicine, Texas A&M University, Houston, Texas.
  • Kim M; HTS Screening Core, Center for Translational Cancer Research, Institute of Biosciences and Technology, College of Medicine, Texas A&M University, Houston, Texas.
  • Umamaheswaran S; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Glassman D; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Wen Y; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Amero P; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Stephan C; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Coleman RL; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Landesman Y; HTS Screening Core, Center for Translational Cancer Research, Institute of Biosciences and Technology, College of Medicine, Texas A&M University, Houston, Texas.
  • Westin SN; US Oncology Research, The Woodlands, Texas.
  • Ram PT; Karyopharm Therapeutics, Newton, Massachusetts.
  • Sood AK; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mol Cancer Ther ; 20(12): 2352-2361, 2021 12.
Article en En | MEDLINE | ID: mdl-34583979
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Ftalazinas / Piperazinas / Triazoles / Protocolos de Quimioterapia Combinada Antineoplásica / Ensayos Analíticos de Alto Rendimiento / Hidrazinas Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Ftalazinas / Piperazinas / Triazoles / Protocolos de Quimioterapia Combinada Antineoplásica / Ensayos Analíticos de Alto Rendimiento / Hidrazinas Tipo de estudio: Prognostic_studies Límite: Animals / Female / Humans Idioma: En Revista: Mol Cancer Ther Asunto de la revista: ANTINEOPLASICOS Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos